Publications by authors named "B Mollenhauer"
Objectives: To determine the impact of dopamine deficiency and isolated REM sleep behavior disorder (iRBD) on cognitive performance in early neuronal alpha-synuclein disease (NSD) with hyposmia.
Methods: Using Parkinson's Progression Markers Initiative baseline data, cognitive performance was assessed with a cognitive summary score (CSS) developed by applying regression-based internal norms derived from a robust healthy control (HC) group. Performance was examined for participants with hyposmia classified as NSD-Integrated Staging System (NSD-ISS) Stage 2, either Stage 2A (CSF alpha-synuclein seed amplification assay [SAA]+, SPECT dopamine transporter scan [DaTscan]-) or 2B (SAA+, DaTscan+).
Article Synopsis
- Leucencephalopathy (LE) is common in elderly Parkinson's patients and can affect deep brain stimulation (DBS) surgery outcomes.
- A study of 135 Parkinson's patients found that 35.6% had LE, mostly mild to moderate, with no significant correlation to surgical complications or effectiveness of DBS treatment.
- The findings suggest that mild to moderate LE should not prevent patients from undergoing DBS surgery, as it does not increase risk or hinder motor function improvement post-surgery.
Article Synopsis
- A novel α-synuclein seed amplification assay (synSAA) was developed to differentiate misfolded α-synuclein seeds linked to multiple system atrophy (MSA) and Parkinson's disease (PD).
- The study analyzed cerebrospinal fluid (CSF) and brain samples from various clinical cohorts across multiple medical centers to assess the assay's diagnostic accuracy.
- Findings showed that brain samples with Lewy bodies were positive for synSAA, indicating potential for the assay in distinguishing between MSA and PD in diagnostic settings.
Background: Preferences for risk disclosure in population-based studies assessing Parkinson's disease (PD) risk have not been assessed so far.
Objectives: To examine preferences for risk disclosure in a subset of the European Healthy Brain Aging (HeBA) multicenter study.
Methods: After a remote PD risk assessment, a structured pilot-questionnaire on risk disclosure was first presented to participants (≥50 years, without neurodegenerative diseases) during in-person visits at the Innsbruck study site.